151 citations,
July 2011 in “Archives of Dermatological Research” Liposomal systems show promise for delivering drugs through the skin but face challenges like high costs and stability issues.
August 2024 in “Drug Design Development and Therapy” Decursin shows promise for treating cancer, neuroprotection, inflammation, and hair loss.
318 citations,
January 2022 in “Signal Transduction and Targeted Therapy” The Wnt/β-catenin pathway is important for body functions and diseases, and targeting it may treat conditions like cancer, but with safety challenges.
128 citations,
March 2006 in “American Journal of Pathology” Prolactin contributes to hair loss by promoting hair follicle shrinkage and cell death.
research Acne
4 citations,
January 2019 Acne is a common skin condition that can be influenced by diet, lifestyle, and hormones, and requires a treatment approach that includes psychological considerations.
119 citations,
November 2014 in “Trends in Cell Biology” Fibroblast growth factor receptor signaling controls cell development and repair, and its malfunction can cause disorders and cancer, but it also offers potential for targeted therapies.
2 citations,
March 2005 in “Cancer biology & therapy” Bexxar treatment led to a high response rate in patients with advanced-stage, treatment-resistant follicular lymphoma.
28 citations,
August 2000 in “Current Opinion in Chemical Biology” Future osteoporosis treatments should focus on increasing bone growth, with many promising options available.
282 citations,
October 2006 in “The Journal of Clinical Endocrinology and Metabolism” The Endocrine Society advised against routine testosterone therapy for women, citing a need for more research on long-term safety and a clear definition of androgen deficiency.
4 citations,
January 2012 in “Elsevier eBooks” The document concludes that various skin conditions have specific treatments, ranging from antihistamines for urticaria to surgery and medication for tumors and chronic skin diseases.
25 citations,
May 2003 in “Expert Opinion on Therapeutic Patents” Steroid Sulfatase inhibitors show promise in treating hormone-dependent disorders like cancers, hair loss, and acne, with 667COUMATE being a potential candidate for breast cancer treatment trials.
6 citations,
September 2005 in “Expert Opinion on Pharmacotherapy” Androgen therapy can help with symptoms like low libido in women, but more research is needed to understand its long-term safety and effects on health.
38 citations,
December 2009 in “Therapeutic Advances in Medical Oncology” The conclusion suggests that prostate cancer should be classified by castration status and that new therapies targeting androgen receptor signaling show promise.
25 citations,
August 2006 in “Human Reproduction” Oral contraceptives lower testosterone levels in women, especially those with certain genetic traits, and may be linked to increased breast cancer risk.
46 citations,
February 2012 in “Oncology Reports” Sorafenib helps some advanced cancers alone or with other treatments, but not all, and research continues to improve its use.
9 citations,
January 2014 in “Annals of Dermatology” Some breast cancer patients on hormonal therapy may develop male or female pattern hair loss, which can sometimes be improved with topical treatments.
March 2011 in “European Urology Supplements” Blood tests for tumor cells could improve prostate cancer diagnosis and treatment; hair loss severity linked to a gene affecting prostate conditions.
March 2011 in “European Urology Supplements” CEC levels may be a useful marker for predicting prostate cancer progression.
January 2000 in “Expert Opinion on Therapeutic Patents” The document highlights various patents for new compounds with potential treatments for multiple diseases, including cancer, hormonal disorders, and diabetes.
22 citations,
October 2018 in “British Journal of Haematology” Women have a higher risk of blood clots from hormonal factors and need careful treatment, especially during pregnancy.
10 citations,
January 2019 in “Archives of Endocrinology and Metabolism” Testosterone therapy may slightly increase sexual desire in women with HSDD but lacks broad recommendation due to safety concerns and limited approval.
March 2011 in “European Urology Supplements” The document concludes that a new biosensor can efficiently detect prostate cancer cells and that standardized referrals help find significant cancers effectively.
14 citations,
December 2010 in “Seminars in Oncology” Rare adrenal cancers that secrete androgens or estrogens have a poor prognosis and are treated primarily with surgery.
93 citations,
June 2001 in “The Journal of Clinical Endocrinology and Metabolism” Certain genetic variations in the AR and ERβ genes can affect androgen levels in women.
29 citations,
July 2013 in “The Journal of Sexual Medicine” Testing for CAG repeat polymorphism in the androgen receptor gene is not currently recommended for managing hypogonadism.
113 citations,
July 2020 in “Communications biology” Men, especially older ones with health issues like prostate cancer, may have worse COVID-19 outcomes and could benefit from therapies targeting male hormones.
21 citations,
November 2014 in “Journal of Endocrinological Investigation” Cross-sex hormone therapy is important for managing gender dysphoria and requires careful monitoring and healthcare provider education.
February 2024 in “BioMetals” Heavy metals like arsenic, cadmium, and lead can increase cancer risk and worsen outcomes.
March 2011 in “European Urology Supplements” Gene variation affects prostate issues and hair loss.
43 citations,
November 2019 in “American Journal of Clinical Dermatology” FAGA diagnosis uses blood tests and trichoscopy, with treatments like topical minoxidil, oral anti-androgens, and hormone-modulating drugs.